Document Detail

p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia.
MedLine Citation:
PMID:  18708411     Owner:  NLM     Status:  MEDLINE    
Management of the patient with oral epithelial dysplasia depends on the ability to predict malignant transformation. Histologic grading of this condition fails in this regard and is also subject to interpathologist and intrapathologist variability. This study uses longitudinal clinical samples to explore the prognostic value of a previously validated panel of methylation biomarkers in a cohort of patients with histologically proven oral dysplasia. Methylation enrichment pyrosequencing assays were used to provide the sensitivity of traditional methylation-specific PCR with the additional specificity advantages of a subsequent confirmatory sequencing reaction. In 57% (8 of 14) patients with a lesion that transformed to oral squamous cell carcinoma, 26% (26 of 100) of longitudinal samples collected over > or =3 years showed p16 methylation. Only 1% (2 of 184) of samples from 8% of patients (2 of 24) not undergoing malignant transformation within 3 years had p16 methylation. Both of these samples with p16 promoter methylation were the most recently collected and the patients remain under continuing clinical review. Promoter methylation of MGMT, CYGB, and CCNA1 did not correlate with malignant progression. We thus conclude that methylation of the p16 gene promoter shows promise as a predictor for malignant transformation (Fisher's exact, P = 0.002) in a subset of patients.
Gillian L Hall; Richard J Shaw; E Anne Field; Simon N Rogers; David N Sutton; Julia A Woolgar; Derek Lowe; Triantafillos Liloglou; John K Field; Janet M Risk
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology     Volume:  17     ISSN:  1055-9965     ISO Abbreviation:  Cancer Epidemiol. Biomarkers Prev.     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-18     Completed Date:  2008-12-16     Revised Date:  2014-02-19    
Medline Journal Info:
Nlm Unique ID:  9200608     Medline TA:  Cancer Epidemiol Biomarkers Prev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2174-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Transformation, Neoplastic / genetics*
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
DNA Methylation*
Mouth Neoplasms / genetics*,  pathology*
Polymerase Chain Reaction
Predictive Value of Tests
Promoter Regions, Genetic / genetics
Prospective Studies
Statistics, Nonparametric
Tumor Markers, Biological / genetics*
Grant Support
G9900432//Medical Research Council
Reg. No./Substance:
0/Cyclin-Dependent Kinase Inhibitor p16; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of language on colorectal cancer screening among Latinos and non-Latinos.
Next Document:  Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human...